Been looking into ways to get exposure to the pharma sector without picking individual stocks, and pharmaceutical etfs are actually a solid option for this. The beauty of it is you get diversification across the whole industry while still trading like a regular stock, which beats holding a bunch of pharma names separately.

The main thing that caught my attention is how these funds handle volatility. Even when individual pharma stocks swing hard, the overall fund tends to stay more stable because of all the different holdings. That's pretty appealing if you're not trying to chase every single price move.

Looking at what's actually available, there are some decent options depending on what kind of exposure you want. The VanEck fund (PPH) has been around since 2011 and holds about 26 companies - top positions are Eli Lilly, Novartis, Merck, and a few others. It's got a pretty low expense ratio too at 0.36 percent.

If you want something with more holdings, the iShares US Pharmaceuticals ETF (IHE) has 45 positions and is weighted heavily toward Johnson & Johnson and Eli Lilly - those two make up almost half the fund. Started back in 2006, so it's been around for a while.

Then there's the Invesco Pharmaceuticals ETF (PJP) which focuses specifically on US-based pharma companies, tracking 31 of them. The top names there are Merck, J&J, Eli Lilly, Pfizer, and Abbott. Pretty solid lineup.

The State Street SPDR fund (XPH) is interesting because it weights its 52 holdings more evenly compared to others, so you're not as heavily concentrated in just a few mega-cap names. And if you're interested in Chinese healthcare exposure, there's the KraneShares China Health Care ETF (KURE) which tracks 50 Chinese healthcare stocks.

The expense ratios across these pharmaceutical etfs are all pretty reasonable, mostly in the 0.35 to 0.65 percent range. What really matters is figuring out which structure fits your strategy - do you want concentrated exposure to the biggest players, or more diversification across smaller positions? That's really the main decision when picking between these options.